This explains the nature of post-NACT residual tumor masses: while short-term platinum therapy does not cause restoration of BRCA1/2 open reading frame via a second mutation, the selection of pre-existing BRCA1/2-proficient tumor cells is observed at significant frequencies [36, 37]. This evidence concerns the gene BRCA1 and neoplasm.